All Videos

Joel Gelfand, MD, MSCE, discussed the role of GLP-1 agonists in addressing the metabolic comorbidities of psoriatic disease at Fall Clinical 2026.

A methodical up-titration schedule and clear expectations help patients reach the point where advanced therapy is appropriate. With no approved CIndU medication, clinicians are extrapolating from CSU.

Second-generation H1 antihistamines remain first-line therapy, yet most patients do not reach control even at higher doses. The panel outlines where antihistamines work, where they stop working, and what that leaves unaddressed.

On this episode of Don’t Be Rash, host Andrew C. Krakowski, MD, welcomes Lawrence Eichenfield, MD, pediatric dermatologist, to discuss topical corticosteroid potency, dosing, and where they fit alongside nonsteroidal agents.

Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker findings for upadacitinib.

At Fall Clinical 2026, Todd Schlesinger, MD, explained recent exosome regulatory progress, the remibrutinib label update for symptomatic dermographism, and ongoing clinical trials at his trial center.

Missed clues, social isolation, and mildly elevated liver enzymes shape the workup of a teenager with confirmed classical EPP. The discussion balances biochemical testing, vitamin D repletion, and realistic photoprotection.

For a functional older patient with recurrent, infiltrative disease after repeated excisions, multidisciplinary review supports hedgehog inhibition with curative intent and a potential path toward less morbid definitive treatment.

A 15-year-old with eight years of light-triggered pain and swelling had been treated for sunscreen allergy, eczema, and sunburn. The case shows how EPP presents and how it differs from other cutaneous porphyrias.

Class-wide laboratory monitoring, a predictable adverse event timeline, and emerging resistance mechanisms shape how hedgehog inhibitor therapy is initiated, sustained, and eventually complemented by agents in development.

A patient with 45 percent hair loss and a wedding in six months illustrates why psychosocial burden can reclassify disease severity and why expectation setting must begin before treatment does.

Dismissing alopecia areata as cosmetic delays appropriate care. Dr. Ungar frames it as an inflammatory autoimmune disease and explains how severity, not scalp percentage alone, should guide the move to systemic therapy.

Which vitiligo patients need oral vs topical JAK inhibitors? Iltefat Hamzavi, MD, shares his approach at Fall Clinical 2026.

Not every flare signals treatment failure. The panel distinguishes manageable fluctuations from true loss of response and weighs how comorbidities and insurance shape next-line biologic selection.

A second patient, initially helped by adalimumab, shows how HS can outpace a first-line biologic over time. The panel discusses recognizing secondary failure and rebuilding a treatment plan.

Along with her Fall Clinical 2026 sessions, Glynis Ablon, MD, discusses combining energy devices with PRP and exosomes, early extended release minoxidil results, and topical stem cell research.

Todd Schlesinger, MD, highlighted the new photodynamic therapy indication for superficial basal cell carcinoma, immunotherapy options for cutaneous squamous cell carcinoma, and sequential actinic keratosis therapy at Fall Clinical 2026.

Age alone should not dictate biologic hesitancy. The panel challenges the assumption that systemic therapies are inherently riskier in older adults, pointing to safety data and the realities of polypharmacy.

An independence-minded 72-year-old with hand arthritis and missed oral doses forces a reassessment of what a workable psoriasis regimen looks like once dexterity and daily routine become limiting factors.

At Fall Clinical 2026, Aaron Farberg, MD, reviewed gene expression profiling in atopic dermatitis and melanoma, and the Ameluz plus PDT approval for superficial basal cell carcinoma.

Adam Friedman, MD, discusses early psoriatic arthritis screening and why long-term data are critical to guiding treatment decisions.

At Fall Clinical 2026, Neal Bhatia, MD, discussed cycle therapy for actinic keratosis, red light photodynamic therapy for superficial basal cell carcinoma, and clinical research pitfalls

At Fall Clinical 2026, Jennifer Hsiao, MD, discussed patient preference, comorbidities, and access guide HS treatment selection.

Ahmad Naim, MD, discussed clinician education, long-term data, and what is next in alopecia areata, HS, and psoriasis.

At Fall Clinical 2026, Christopher Bunick, MD, PhD, discussed topical and oral acne management, including tetracycline selection and micronized isotretinoin.

At Fall Clinical 2026, Glynis Ablon, MD, recommends body dysmorphic disorder screening and systematic documentation in aesthetics, plus early combination therapy for multifactorial alopecia.

At Fall Clinical 2026, Shannon Trotter, DO, reviews locally advanced and metastatic cutaneous squamous cell carcinoma, immune checkpoint inhibitors, and proposed Medicare cuts affecting skin cancer care.

Christopher Bunick, MD, PhD, presented long-term safety data for JAK inhibitors upadacitinib and abrocitinib in atopic dermatitis at Fall Clinical 2026.

Jennifer Hsiao, MD, explains how defining HS treatment response improves adherence and success.

At Fall Clinical 2026, Raj Chovatiya, MD, PhD, MSCI, urged clinicians to understand the data and consider systemic therapy in atopic dermatitis.